Entelos, Inc. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,774,182, entitled "Apparatus and Method for Validating a Computer Model." This patent was issued to Entelos for its invention of an innovative computer-implemented method for validating multiple virtual patients within a computer model. The PhysioLab® virtual patient technology allows Entelos life scientists and engineers to more rapidly evaluate the safety and efficacy of new therapeutics in a diverse population of patients. This predictive power is integrated into our PhysioLab platforms, which have been used by our pharmaceutical and consumer product customers for over a decade to dramatically reduce the risk, time, and cost of product development.
“This patent represents a key step in protecting the Company's core, groundbreaking virtual patient technology”
"This patent represents a key step in protecting the Company's core, groundbreaking virtual patient technology," said Tom Paterson, Entelos' Co-Founder and Chief Technology Officer. "Virtual patients and virtual populations are a foundational layer for Entelos' suite of solutions that are being applied by our customers across a number of applications, including pharmaceutical and consumer product research and development."
"Our automated validation method has allowed us to more efficiently expand the scale of our work into whole virtual populations and clinical trial simulations," stated Julie Thomas, Entelos' Chief Executive Officer. "These clinical simulations enable our customers to run more efficient trials and save a significant amount of time and money in pharmaceutical and consumer product development. Virtual populations also bring us one step closer to our goal of applying our world-class technology across multiple vertical applications, including compound rescue, financial applications, and personalized medicine."
Generative AI falls short in accurately identifying global health policies